Cevostamab

Drug Overview

Cevostamab is a highly advanced, experimental medication currently being studied for the treatment of multiple myeloma, a type of blood cancer. It belongs to an innovative class of drugs called Immunotherapy or Targeted Therapy. Unlike traditional chemotherapy that attacks all fast-growing cells, cevostamab acts as a bridge that connects the body’s own immune system directly to the cancer cells, helping the body fight the disease naturally.

While it is still being evaluated in clinical trials (such as the CAMMA and STEM studies), it has shown great promise for patients whose cancer has returned (relapsed) or stopped responding to multiple other treatments (refractory).

Here are the key details about this medication:

• Generic Name: Cevostamab (also known in research by its development codes BFCR4350A or RO7187797).
• US Brand Names: None yet. Because it is still in clinical trials, a commercial brand name has not been officially assigned.
• Drug Class: Bispecific T-cell Engager (BiTE) / Bispecific Antibody.
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Currently investigational. It is not yet approved by the US Food and Drug Administration (FDA) for general public use, but it is actively being studied in late-stage clinical trials.

What Is It and How Does It Work? (Mechanism of Action)

Cevostamab is a “Smart Drug” designed to outsmart cancer by utilizing the patient’s own immune system. To understand how it works at the molecular level, it helps to look at the unique shape of the drug.

Cevostamab is a bispecific antibody. The prefix “bi-” means two. This means the drug has two different “arms” that bind to two specific, distinct targets in the body at the same time:

1. Arm 1 (Finding the Cancer): One arm of the cevostamab molecule targets and attaches to a specific protein called FcRH5. This protein is highly overexpressed (found in large amounts) on the surface of multiple myeloma cancer cells, but it is rarely found on healthy tissues. This allows the drug to home in precisely on the tumor.
2. Arm 2 (Calling the Immune System): The second arm targets a protein called CD3, which is found on the surface of T-cells. T-cells are the powerful “soldier” cells of the human immune system, responsible for destroying threats.
3. The Attack: By holding onto the cancer cell with one arm and the immune T-cell with the other, cevostamab forces the two cells together. This creates an “immunological synapse.”
4. Cellular Destruction: Once forced into direct contact, the T-cell becomes activated. It releases toxic enzymes (called perforins and granzymes) directly into the myeloma cell, causing the cancer cell to break apart and die.

FDA-Approved Clinical Indications

Because cevostamab is an investigational drug, it does not currently have official FDA-approved indications for routine clinical practice. However, it is being extensively studied in clinical trials for the following areas:

• Oncological Uses (In Clinical Trials):
  • Relapsed or Refractory Multiple Myeloma (RRMM): Used for patients whose cancer has come back or stopped responding to at least three previous types of therapy (triple-class refractory).
  • Post-CAR T-cell Consolidation: Used in patients who have previously received CAR T-cell therapy or other BCMA-targeted treatments to deepen and maintain their cancer remission.
• Non-oncological Uses:
  • None at this time. The drug is exclusively being studied for blood cancers.

Dosage and Administration Protocols

Because cevostamab is an investigational therapy, dosing is carefully controlled under clinical trial protocols. To prevent a shock to the immune system, the drug is usually given in “step-up” doses, starting with a very small amount and slowly increasing to a target dose.

Clinical Efficacy and Research Results

Recent clinical studies (between 2023 and 2025) highlight the powerful impact of cevostamab, particularly for patients who have exhausted standard treatment options.

• High Response Rates: In the Phase 1 CAMMA studies evaluating heavily pretreated patients, cevostamab demonstrated an Overall Response Rate (ORR) ranging from 43% to 56.7% at target doses. This means roughly half of the patients saw their tumors shrink significantly.
• Post-CAR T Therapy Success: The 2024-2025 STEM trial looked at patients who received cevostamab after standard CAR T-cell therapy. The results were highly promising: over 90% of evaluated patients achieved a sustained “MRD-negative complete response” at one year. This means their cancer was undetectable even at a microscopic level.
• Targeting Resistant Cancer: Cevostamab has proven effective even in patients whose cancer progressed after previous advanced treatments, showing a 73% response rate in patients who previously received CAR-T cell therapy.

Safety Profile and Side Effects

Because cevostamab powerfully activates the immune system, it can cause distinct side effects that require careful medical management.

Common Side Effects (>10%)

• Cytokine Release Syndrome (CRS): Experienced by over 50% to 70% of patients. When T-cells attack cancer, they release chemicals called cytokines, causing flu-like symptoms (fever, chills, body aches). Most cases are mild to moderate (Grade 1 or 2) and occur during the first few doses.
• Cytopenias (Low Blood Counts): Includes neutropenia (low white blood cells, ~31%), anemia (low red blood cells), and thrombocytopenia (low platelets).
• Infections: Because the immune system is altered, patients have a higher risk of respiratory infections (like pneumonia or COVID-19) and urinary tract infections.
• Fatigue: Mild to moderate tiredness.

Serious Adverse Events

• Severe CRS: While rare with “triple step-up” dosing, severe CRS can cause dangerously low blood pressure or difficulty breathing.
• Severe Infections: High-grade infections requiring hospitalization and intravenous antibiotics.

Black Box Warning

• As an investigational agent, cevostamab does not currently carry an FDA Black Box Warning. However, drugs in the bispecific T-cell engager class typically carry severe warnings regarding Cytokine Release Syndrome and neurologic toxicities.

Management Strategies

• Premedication: Patients are routinely given corticosteroids, acetaminophen, and antihistamines (like diphenhydramine) before their infusion to prevent allergic reactions and reduce the risk of CRS.
• CRS Treatment: If a patient develops CRS, doctors can quickly administer a specialized rescue drug called tocilizumab, which rapidly calms the immune system down.
• Infection Prevention: Patients with low antibodies may be given intravenous immunoglobulin (IVIG) to boost their ability to fight off infections.

Connection to Stem Cell and Regenerative Medicine

Cevostamab has an exciting connection to cellular immunotherapy and regenerative medicine, specifically regarding CAR T-cell therapy. CAR T-cell therapy involves genetically modifying a patient’s own stem/immune cells to fight cancer. While CAR T-cell therapy is highly effective, the cancer sometimes returns if the modified cells stop working. Current trials, like the STEM trial, are combining these two approaches. By administering cevostamab as a “consolidation therapy” a few months after CAR T-cell infusion, doctors are using cevostamab to keep the immune system active and eliminate any lingering, microscopic cancer cells, aiming for a longer-lasting cure.

Patient Management and Practical Recommendations

To ensure the highest safety and best possible outcome, patients participating in cevostamab clinical trials must follow specific medical guidelines.

Pre-treatment Tests to be Performed

• Bone Marrow Biopsy: Required to check the percentage of cancer cells in the marrow.
• Comprehensive Blood Panels: To check baseline liver, kidney, and blood cell counts.
• Pregnancy Test: A negative pregnancy test is strictly required for women of childbearing age, as the drug can harm an unborn baby.

Precautions During Treatment

• Hospital Stay: You must stay in the hospital for at least 48 hours during your first few “step-up” doses so doctors can monitor you closely for Cytokine Release Syndrome (CRS).
• Infection Risk: Your immune system will be fragile. You must take extra care to avoid crowds, sick individuals, and undercooked foods.

“Do’s and Don’ts” List

• DO report any fever, chills, dizziness, or shortness of breath to your medical team immediately. These are early signs of CRS and need prompt treatment.
• DO drink plenty of fluids and practice excellent personal hygiene to reduce the risk of infection.
• DO keep all scheduled lab appointments, as your blood counts will need to be checked frequently.
• DON’T receive any “live” vaccines without explicit permission from your oncologist.
• DON’T ignore minor symptoms like a cough or a burning sensation when urinating, as these could be signs of a developing infection.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Cevostamab is an investigational therapeutic agent and is not currently approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for general clinical use. It is available only through participation in approved clinical trials. Always consult with a qualified healthcare professional or your treating oncologist regarding diagnosis, treatment options, potential side effects, and eligibility for clinical trials.